Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumours (MK-4280-001)

Official Title

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumours

Summary:

This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumours for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive favezelimab as monotherapy or favezelimab in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RP2D), as determined by dose-limiting toxicity, for favezelimab in combination with pembrolizumab or pembrolizumab and lenvatinib in participants with advanced solid tumours. Part B will also assess the efficacy of favezelimab as monotherapy; favezelimab in combination with pembrolizumab with and without chemotherapy; favezelimab in combination with pembrolizumab and lenvatinib; and favezelimab/pembrolizumab as monotherapy in expansion cohorts.

Trial Description

Primary Outcome:

  • Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
  • Number of Participants Who Experience at Least One Adverse Event (AE)
  • Number of Participants Who Discontinue Study Drug Due to an AE
Secondary Outcome:
  • Serum Concentration of Favezelimab When Administered as Monotherapy
  • Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab
  • Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and mFOLFOX7
  • Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and FOLFIRI
  • Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and Lenvatinib
  • Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and mFOLFOX7
  • Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and FOLFIRI
  • Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and Lenvatinib
  • Serum Concentration of Lenvatinib When Administered in Combination With Pembrolizumab and Favezelimab
  • Objective Response Rate (ORR) as Determined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1) as Assessed by Investigator Review of Favezelimab Alone and in Combination With Pembrolizumab
  • ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Two Doses of Favezelimab in Combination With Pembrolizumab for Participants With Advanced Solid Tumours in Cohort E
  • ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and mFOLFOX7 for Participants With Advanced Solid Tumours in Cohort B
  • ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and FOLFIRI for Participants With Advanced Solid Tumours in Cohort B
  • ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and Lenvatinib for Participants With Advanced Solid Tumours in Cohort G
  • Serum Concentration of Favezelimab When Administered as a Co-Formulation With Pembrolizumab (MK-4280A)
  • Serum Concentration of Favezelimab When Administered Sequentially With Pembrolizumab
  • Serum Concentration of Pembrolizumab When Administered as a Co-Formulation With Favezelimab (MK-4280A)
  • Serum Concentration of Pembrolizumab When Administered Sequentially With Favezelimab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society